Literature DB >> 26173376

Guidelines for urinary tract infections and antenatal hydronephrosis should be gender specific.

Shiran S Moore1,2, Hilla Bahat2,3, Mariana Rachmiel2,3, Tomer Ziv-Baran4, Ilan Youngster2,3, Michael Goldman2,3.   

Abstract

AIM: Febrile urinary tract infections (UTIs) may be associated with long-term renal damage. Our goal was to identify risk factors for future UTIs in children who had voiding cystourethrography (VCUG) as a part of an antenatal hydronephrosis (ANH) assessment or after a febrile UTI.
METHODS: We conducted a cohort study based on the medical records of children aged 0-24 months who underwent a VCUG between January 2004 and December 2011 and had at least six months of follow-up. The incidence of future UTIs was assessed.
RESULTS: We included 285 children: 176 had a primary UTI and 109 had ANH. We recorded 28 UTIs during the follow-up period, and the risk was 12.5% after a primary UTI and 5.5% after an ANH (p = 0.049). Multivariate analysis showed no risk difference was found between the groups. Females had a greater risk of febrile UTIs (hazard ratio 3.3, 95% confidence interval 1.03-9.2, p = 0.04), but the UTI risk did not differ between children with or without VURs.
CONCLUSION: Female infants were at greater risk of febrile UTIs, regardless of the presence of VUR, VUR degree, ANH or a previous UTI. Clinical guidelines for UTI and ANH assessment should preferably be gender specific. ©2015 Foundation Acta Paediatrica. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  Antenatal hydronephrosis; Renal scaring; Urinary tract infection; Vesicoureteral reflux; Voiding cystourethrography

Mesh:

Year:  2015        PMID: 26173376     DOI: 10.1111/apa.13129

Source DB:  PubMed          Journal:  Acta Paediatr        ISSN: 0803-5253            Impact factor:   2.299


  1 in total

1.  Paediatrics: Guidelines for UTI and antenatal hydronephrosis should be gender specific.

Authors:  Maria Christodoulou
Journal:  Nat Rev Urol       Date:  2015-08-18       Impact factor: 14.432

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.